WO2010082804A3 - Method for producing physiologically active protein or peptide using immunoglobulin fragment - Google Patents

Method for producing physiologically active protein or peptide using immunoglobulin fragment Download PDF

Info

Publication number
WO2010082804A3
WO2010082804A3 PCT/KR2010/000342 KR2010000342W WO2010082804A3 WO 2010082804 A3 WO2010082804 A3 WO 2010082804A3 KR 2010000342 W KR2010000342 W KR 2010000342W WO 2010082804 A3 WO2010082804 A3 WO 2010082804A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
physiologically active
method
active protein
immunoglobulin fragment
Prior art date
Application number
PCT/KR2010/000342
Other languages
French (fr)
Other versions
WO2010082804A2 (en
Inventor
Jin-Sun Kim
Sung Youb Jung
Jong-Soo Lee
Byung Sun Lee
Se Chang Kwon
Gwan Sun Lee
Original Assignee
Hanmi Holdings Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR10-2009-0004234 priority Critical
Priority to KR20090004234 priority
Application filed by Hanmi Holdings Co., Ltd filed Critical Hanmi Holdings Co., Ltd
Publication of WO2010082804A2 publication Critical patent/WO2010082804A2/en
Publication of WO2010082804A3 publication Critical patent/WO2010082804A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention provides a method for mass-producing a physiologically active protein or peptide using a fusion protein composed of the physiologically active protein or peptide and an immunoglobulin fragment. The present invention also provides such a fusion protein, a DNA encoding the fusion protein, an expression vector comprising the DNA, and a microorganism transformed with the expression vector.
PCT/KR2010/000342 2009-01-19 2010-01-19 Method for producing physiologically active protein or peptide using immunoglobulin fragment WO2010082804A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR10-2009-0004234 2009-01-19
KR20090004234 2009-01-19

Publications (2)

Publication Number Publication Date
WO2010082804A2 WO2010082804A2 (en) 2010-07-22
WO2010082804A3 true WO2010082804A3 (en) 2010-11-25

Family

ID=42340231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000342 WO2010082804A2 (en) 2009-01-19 2010-01-19 Method for producing physiologically active protein or peptide using immunoglobulin fragment

Country Status (4)

Country Link
KR (1) KR20100084996A (en)
AR (1) AR075029A1 (en)
TW (1) TW201031752A (en)
WO (1) WO2010082804A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US20050124045A1 (en) * 2001-08-17 2005-06-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with increased biological activities
US20060269553A1 (en) * 2003-11-13 2006-11-30 Hanmi Pharm. Ind. Co., Ltd. Protein complex using an immunoglobulin fragment and method for the preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US20050124045A1 (en) * 2001-08-17 2005-06-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with increased biological activities
US20060269553A1 (en) * 2003-11-13 2006-11-30 Hanmi Pharm. Ind. Co., Ltd. Protein complex using an immunoglobulin fragment and method for the preparation thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LO K. M. ET AL PROTEIN ENGINEERING vol. 11, no. 12, June 1998, pages 495 - 500 *

Also Published As

Publication number Publication date
AR075029A1 (en) 2011-03-02
WO2010082804A2 (en) 2010-07-22
TW201031752A (en) 2010-09-01
KR20100084996A (en) 2010-07-28

Similar Documents

Publication Publication Date Title
MX2007000728A (en) Biosynthetic polypeptides utilizing non-naturally encoded amino acids.
TW201446793A (en) FGF21 mutants and uses thereof
TW201346032A (en) Cell culture improvements
IL201340D0 (en) Cross - species - specific cd3 - epsilon binding domain
WO2009149171A4 (en) Fgf21 mutants and uses thereof
WO2007067314A3 (en) Ion sources, systems and methods
MX2011011815A (en) Fgf21 mutants and uses thereof.
NZ600731A (en) Oxyntomodulin peptide analogue
IL190732D0 (en) Immunomodulation using placental stem cells
WO2010042747A3 (en) Fgf21 mutants and uses thereof
WO2006053301A3 (en) Fc variants with altered binding to fcrn
WO2006046148A3 (en) Rna constructs
WO2009155724A3 (en) Stable and soluble antibodies inhibiting vegf
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
WO2005001025A3 (en) Immunoglobulin chimeric monomer-dimer hybrids
EP1989301A4 (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
MX2013015366A (en) Heterodimerized polypeptide.
WO2012158818A3 (en) Multi-specific fab fusion proteins and methods of use
WO2011012316A3 (en) Rna with a combination of unmodified and modified nucleotides for protein expression
WO2004029207A3 (en) Optimized fc variants and methods for their generation
EP2205744A4 (en) Xylanases, nucleic acids encoding them and methods for making and using them
MX2008012843A (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods.
EP2535351A3 (en) Dual specificity antibody fusions
IL205866D0 (en) Antibodies against human nkg2d and uses thereof
EP1814586A4 (en) Anti-properdin antibodies, and methods for making and using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10731419

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 10731419

Country of ref document: EP

Kind code of ref document: A2